Stockscreener 앱 받기
147.04
7.84%
10.74
전일 마감가:
$136.30
열려 있는:
$136.5
하루 거래량:
6.39M
Relative Volume:
2.02
시가총액:
$29.13B
수익:
$742.00K
순이익/손실:
$-1.13B
주가수익비율:
-24.85
EPS:
-5.9165
순현금흐름:
$-913.73M
1주 성능:
+52.64%
1개월 성능:
+54.94%
6개월 성능:
+209.43%
1년 성능:
+303.02%
1일 변동 폭
$134.66
$147.12
1주일 범위
$94.63
$147.12
52주 변동 폭
$34.00
$147.12
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
650-481-6801
주소
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
146.99 | 19.11B | 742.00K | -1.13B | -913.73M | -5.9165 |
VRTX
Vertex Pharmaceuticals Inc
|
443.06 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
829.67 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
337.73 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.48 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-02-27 | 재개 | UBS | Buy |
| 2025-11-18 | 개시 | Wolfe Research | Outperform |
| 2025-11-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-12 | 재개 | Raymond James | Strong Buy |
| 2025-09-05 | 개시 | Truist | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-08-15 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
Investors Purchase High Volume of Revolution Medicines Call Options (NASDAQ:RVMD) - MarketBeat
RVMD Maintains by RBC Capital -- Price Target Raised to $162 - GuruFocus
RVMD Maintained by Wells Fargo -- Price Target Raised to $167 - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Given New $167.00 Price Target at Wells Fargo & Company - MarketBeat
Revolution Medicines Stock Soars on Breakthrough Cancer Data - TipRanks
RVMD Maintained by Evercore ISI Group -- Price Target Raised to $200 - GuruFocus
RVMD Reiterated by Wedbush -- Price Target Maintained at $147.00 - GuruFocus
RVMD Maintained by Guggenheim -- Price Target Raised to $175 - GuruFocus
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report) - FinancialContent
Why Did Oncology Stock Revolution Medicines (RVMD) Gain 41% Monday? - Investorideas.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
RVMD Maintained by HC Wainwright & Co. -- Price Target Raised to $169 - GuruFocus
RBC Raises Price Target on Revolution Medicines to $162 From $140, Keeps Outperform, Speculative Risk - marketscreener.com
H.C. Wainwright raises Revolution Medicines price target to $169 - Investing.com
Pancreatic cancer pill shown to nearly double overall survival time, drug company says - The Hill
H.C. Wainwright raises Revolution Medicines price target to $169 By Investing.com - Investing.com Canada
Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed? - Yahoo Finance
Revolution Medicines Doubles Pancreatic Cancer Survival in Phase 3 Trial — Is RVMD Stock a Buy at $136? - TradingKey
Baillie Gifford & Co. Invests $15.53 Million in Revolution Medicines, Inc. $RVMD - MarketBeat
US biotech seeks quick FDA approval after improved survivability with cancer candidate - medwatch.com
Revolution Medicines Stock Surges After Trial Data: Is Biotech Back? - EBC Financial Group
Revolution Medicines (RVMD) Sees Potential Surge Following Phase III Trial Success - GuruFocus
Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial - Insider Monkey
Revolution Medicines (RVMD) Plans $1 Billion in Offerings to Bol - GuruFocus
Revolution’s daraxonrasib nails endpoints in pancreatic cancer trial - BioWorld News
Revolution Medicines plans $1 billion dual offering By Investing.com - Investing.com India
RVMD Stock Jumps As Analysts Hike Price Targets On Pancreatic Cancer Bets - timothysykes.com
Revolution Medicines shares pop after pancreatic cancer drug trial win - CNBC
Revolution Medicines shares jump on breakthrough pancreatic cancer trial results - MSN
Revolution Medicines, Inc. Announces Proposed Offerings Of Common Stock And Convertible Senior Notes - TradingView — Track All Markets
Revolution Medicines plans $1B combined equity and convertible note offerings - MSN
Revolution Medicines (RVMD) files $750M share sale; $250M convertible notes planned - Stock Titan
Revolution Medicines (NASDAQ: RVMD) seeks $250M via convertible notes, concurrent $750M stock sale - Stock Titan
Revolution Medicines plans $1 billion dual offering - Investing.com
Top Biotech Catapults On 'Unprecedented' Results In Cancer - Investor's Business Daily
Revolution Medicines Announces Unprecedented Survival Gains with Daraxonrasib in Late-Stage Pancreatic Cancer Study - BBN Times
U.S. Markets Rose Monday; Revolution Medicines Topped Leaders - Barron's
Leerink Partners Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $147.00 - MarketBeat
Revolution Medicines seeks $1B to fund cancer-drug R&D, launch prep - Stock Titan
Revolution Medicines Reports ‘Unprecedented’ Survival in Pivotal Pancreatic Cancer Trial - MedCity News
Revolution Medicines Soars on Phase 3 Trial Results. Is It Too Late to Buy? - Barchart.com
Revolution Medicines stock hits all-time high at 132.41 USD By Investing.com - Investing.com Australia
RVMD Stock Rallies As Analysts Hike Price Targets On Trial Momentum - timothysykes.com
RVMD Maintained by Oppenheimer -- Price Target Raised to $165 - GuruFocus
Revolution Medicines (RVMD) Stock Surges 38.7% - GuruFocus
Revolution Medicines surges 38% on pancreatic cancer breakthrough - CryptoRank
Revolution Medicines Announces Breakthrough in Pancreatic Cancer Treatment with daraxonrasib - GuruFocus
Revolution Medicines (RVMD) Sees Remarkable 37.9% Surge - GuruFocus
Revolution Medicines: PDAC Data Wows Wall StreetJury's Out On Further Upside (RVMD) - Seeking Alpha
RVMD Stock Jumps As Analysts Hike Targets On Trial Hopes - StocksToTrade
Revolution Medicines reports positive Phase 3 results for daraxonrasib in pancreatic cancer By Investing.com - Investing.com India
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.01%
자본화:
|
볼륨(24시간):